Leading alternative asset manager Trinity Capital announced the commitment of up to $68.75 million in growth capital to CMR Surgical, a global medical devices company dedicated to transforming surgery with the Versius Surgical Robotic System, an adaptable soft-tissue surgical robot. This investment forms part of the company’s recently closed financing round of over $200 million.
Based in Cambridge, United Kingdom, CMR Surgical is dedicated to collaborating with surgical teams and hospital partners to make robotic minimal access surgery universally accessible and affordable. The company was recently granted marketing authorization by the U.S. Food and Drug Administration (FDA) for the use of Versius in Cholecystectomy, paving the way for the introduction of its next-generation digitally driven surgical robot in the US.
This growth capital enables CMR Surgical to continue scaling operations and accelerating the commercial expansion of its Versius Surgical Robotic System to more hospitals around the world, with a major focus on launching Versius in the US.
KEY QUOTES:
“CMR Surgical’s innovative approach and consistent progress in surgical robotics demonstrate a promising trajectory in the medtech sector, as they empower hospitals and surgeons with greater access to next-generation technology.”
– Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital
“CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalize on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to thank Trinity Capital for their support and for their belief in our strategic vision of making robotic assisted surgery accessible to all patients who need it.”
– Massimiliano Colella, Chief Executive Officer at CMR Surgical
